Results 161 to 170 of about 194,026 (392)

Smart REASSURED Sensors via Machine‐Augmented Printable On‐Paper Arrays

Advanced Sensor Research, EarlyView.
This perspective highlights the emerging role of pattern‐recognition, printable on‐paper sensor arrays for intelligent PoC diagnostics. It discusses how paper's inherent limitations can be overcome through surface modification and scalable printing, and how machine‐learning analysis of cross‐reactive arrays enables multiplexed, low‐cost, and REASSURED ...
Naimeh Naseri, Saba Ranjbar
wiley   +1 more source

The Effect of Combined Therapy with a Proton Pump Inhibitor and Rebamipide on the Clinical Course and Morphofunctional Changes of the Esophageal Mucosa in Patients with Non-Erosive Reflux Disease

Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Aim: to evaluate the effect of combined therapy with a proton pump inhibitor and rebamipide on clinical manifestations and morphofunctional changes in the esophageal mucosa in patients with non-erosive reflux disease.Materials and methods.
A. A. Makushina, A. S. Trukhmanov, A. B. Ponomarev, O. A. Storonova, A. V. Paraskevova, P. G. Ermishina, V. A. Mironova, V. T. Ivashkin   +7 more
doaj   +1 more source

An Exploratory Analysis of Pharmaceutical Price Disparities and Their Implications Among Six Developed Nations [PDF]

In our study of 43 drugs, prescription drug prices in several wealthy nations (Australia, Canada, France, Germany, and the U.K.) were much lower than in the U.S. on average, well below relative per capita GDP. There was relatively little difference among
Calfee, John E., DuPr�, Elizabeth, Villarreal, Mario   +2 more
core   +1 more source

Symptoms in patients on long‐term proton pump inhibitors: prevalence and predictors [PDF]

, 2008
Anan Raghunath, A. P. S. Hungin, James Mason, Warren Jackson   +3 more
openalex   +1 more source

Proton-pump inhibitor-responsive esophageal eosinophilia [PDF]

, 2020
INSERM
openalex   +1 more source

Regulating Tumor Metabolic Reprogramming with Biomimetic Co‐Delivery of Simvastatin and Kynureninase for Immunotherapy

Advanced Science, EarlyView.
After the intravenous injection of biomimetic and pH/ROS‐responsive PTSK@CRM, the nanoparticles can be accumulated in tumors and release Sim and KYNase to inhibit the tumor growth, regulate the metabolism of cholesterol and Kyn, and reverse the immunosuppressive tumor microenvironment.
Jiaxin Yin, Shengcai Yang, Zengguang Liu, Songchen Zhao, Siyu Sun, Ziling Liu, Quanshun Li   +6 more
wiley   +1 more source

Do Proton Pump Inhibitors Exacerbate Nonsteroidal Anti-Inflammatory Drug-Induced Small-Bowel Enteropathy? [PDF]

, 2016
Francis K.L. Chan
openalex   +1 more source

The association between proton pump inhibitors and hyperparathyroidism: a potential mechanism for increased fracture—results of a large observational cohort study [PDF]

, 2023
Donal Fitzpatrick, Rosaleen Lannon, Éamon Laird, Mary Ward, Leane Hoey, Catherine Hughes, JJ Strain, Conal Cunningham, Helene McNulty, Anne M. Molloy, Kevin McCarroll   +10 more
openalex   +1 more source

PARPi Combining Nanoparticle LIN28B siRNA for the Management of Malignant Ascites

Advanced Science, EarlyView.
This study demonstrates that co‐inhibition of LIN28B and PARP using siLin28b/DSSP@lip‐PEG‐FA nanoparticles in combination with the PARP inhibitor BMN673 effectively suppresses the accumulation of malignant ascites associated with advanced cancers.
Yan Fang, Qian Shen, Yao Lin, Jing Zhu, Xiaolan Zhu, Rui Huang, Yijia Wu, Feiyang Shen, Qian Li, Guopei Zheng, Zhe Zhang, Qian Chu, Junhao Hu, Jianfeng Shen   +13 more
wiley   +1 more source

Inappropriate use of proton-pump inhibitors and fragility fracture risk. A preliminary study [PDF]

, 2015
Introducción: Los inhibidores de la bomba de protones (IBP) son fármacos ampliamente utilizados, si bien esto conlleva a un sobreuso que no es acorde con las indicaciones aceptadas en España y en el resto de Europa.
Gómez de Tejada Romero, María Jesús
core